Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-playhouse drug development company built on a course of life pharmacology technology platform, today announced that the primeval patient has been dosed in a Phase 2a grief of CAT-2054 for the treatment of hypercholesterolemia. CAT-2054 is each oral small molecule that modulates the SREBP path. SREBP is a master regulator of lipid metabolism that impacts LDL, triglycerides and diabetic sugar with the potential to impact liver heavy and hepatocellular carcinoma.
The CAT-2054 Phase 2a test is a 4-week randomized, double-benighted, placebo-controlled trial in patients with hypercholesterolemia. Catabasis plans to enroll nearly 150 patients that will receive human being of four doses of CAT-2054 or placebo, the pair in addition to a stable disagreeable lot of a high intensity statin, atorvastatin 40 mg through day. The primary efficacy endpoint because this trial will be percent subdual in LDL cholesterol. Catabasis will too explore the activity of CAT-2054 forward other metabolic parameters such as triglycerides and diabetic sugar.
“Compared with currently approved cholesterol drugs, CAT-2054 represents a modern pharmacologic approach to treating dyslipidemia,” afore~ Harold Bays, M.D., Medical Director / President of the Louisville Metabolic and Atherosclerosis Research Center Inc. “Based adhering the encouraging Phase 1 study results, and the continued unmet want in treating patients with abnormal lipid levels, we anticipate forward to participating as a inquiry site in evaluating this agent.”
“CAT-2054, via its modulation of SREBP activity, has the potential to impact LDL cholesterol, triglycerides and diabetic sugar metabolism,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis Pharmaceuticals. “The indoctrination of the Phase 2a trial is one important milestone in the development of CAT-2054 and signifies that we are undivided step closer to potentially providing a new oral treatment option to patients by hypercholesterolemia.”
More information about the CAT-2054 Phase 2a burden can be found on ClinicalTrials.gov for that which is less than trial identifier NCT02608697.
CAT-2054 is some investigational oral drug initially being developed by reason of the treatment of hypercholesterolemia in patients towards whom existing therapies are insufficient. By modulating the SREBP pathway, CAT-2054 may inhibit production of important cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase and NPC1L1. If approved, CAT-2054 may obtain the potential to be the primeval therapy to simultaneously modulate cholesterol combination , clearance and absorption. Catabasis is currently conducting a Phase 2a trial of CAT-2054 in etc. to high intensity statin therapy in patients with hypercholesterolemia. Catabasis has previously reported certain top-line Phase 1 data.
Catabasis Pharmaceuticals is a clinical-platform biopharmaceutical company focused on the first view, development and commercialization of novel therapeutics using its see preprinter Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based without interrupti~ the concept of treating diseases ~ the agency of simultaneously modulating multiple targets in united or more related disease pathways. The Company engineers bi-functional proceeds candidates that are conjugates of pair molecules, or bioactives, each with known pharmacological action, joined by one of its see preprinter SMART linkers. The SMART linker kindred words are designed for enhanced efficacy and improved close custody and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the method of treating of serious lipid disorders. For other information on the Company’s technology and pipeline of deaden with narcotics candidates, please visit www.catabasis.com.
Forward Looking Statements
Any statements in this squeeze out release about future expectations, plans and prospects because of the Company, including statements about coming events clinical trial plans, the potential curative effectiveness of CAT-2054 and other statements containing the language “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements not beyond the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may deviate materially from those indicated by such forward-looking statements as a rise of various important factors, including: uncertainties innate in the initiation and completion of preclinical studies and clinical trials and clinical evolution of the Company’s product candidates, including CAT-2054; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial desire be predictive of the final results of the heartache or the results of future trials; expectations because regulatory approvals to conduct trials of or to emporium CAT-2054; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and excellent expenditure requirements; other matters that could alter the availability or commercial potential of CAT-2054; and ordinary economic and market conditions and other factors discussed in the “Risk Factors” portion of the Company’s Quarterly Report ~ward Form 10-Q for the three months ended September 30, 2015, what one. is on file with the Securities and Exchange Commission, and in other filings that the Company may do the part of with the Securities and Exchange Commission in the coming time. In addition, the forward-looking statements included in this embrace closely release represent the Company’s views in the same manner with of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to modify. However, while the Company may appointed to update these forward-looking statements at some point in the future, the Company specifically disclaims a single one obligation to do so. These earnest-looking statements should not be relied about as representing the Company’s views for the re~on that of any date subsequent to the time of this release.
View source reading on businesswire.com: http://www.businesswire.com/information/home/20151209005649/en/
I had to propel 200 miles to get decent broadband, from Surrey to Mid Wales and to influence away from full VM service.